Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Chemoradiotherapy for Advanced Oropharyngeal and Hypopharyngeal Cancer
NCT01516996Phase 2Unknown
- Sponsor
- Second People's Hospital of Sichuan
- Start
- Mar 2012
- Primary completion
- Sep 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in oropharyngeal squamous cell carcinoma (OPSCC), hypopharyngeal squamous cell carcinoma (HSCC), sponsored by Second People's Hospital of Sichuan. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT01516996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01516996.